PET/CT with long field of view

长视场 PET/CT

• 批准号: 445471454
• 金额: --
• 依托单位: Eberhard Karls Universität Tübingen
• 依托单位国家: 德国
• 项目类别: Major Research Instrumentation
• 财政年份: 2021
• 资助国家: 德国
• 起止时间: 2020-12-31 至 无数据
• 项目状态: 未结题
• 来源: https://gepris.dfg.de/gepris/projekt/445471454?language=en
• 关键词: PET; CT; long; field; view

Positron-Emission-Tomography (PET) enables the detection of metabolic changes in vivo with high sensitivity and specificity, by using radiolabelled tracers (radiopharmaceuticals), which can specifically detect metabolic changes of different diseases or are directed against specific target structures (antigens or receptors). PET is considered to be the most accurate method for the non-invasive assessment of spatial and temporal metabolic changes in vivo. The requested PET/CT scanner has a significantly larger axial field of view (FOV) of 1 m compared to cur-rently available devices (FOV 25 cm), and thus will come with a 10-fold higher sensitivity as well as a considerably improved spatial and temporal resolution. Therefore, a previously unattained image quality for the detection of molecular changes can be achieved, even in comparison with a similar prototype with a FOV of 2 m. Thus, novel examination procedures with PET/CT can be carried out and further developed, which are not possible with the currently available technology:• Ultra-fast whole-body PET-examinations (1-2 min instead of 20 min), with unchanged amount of radiopharmaceuticals administered• Ultra-low dose PET examinations with very low radiation exposure (0.5 mSv instead of 6-12 mSv), as the higher sensitivity enables a considerable reduction in the amount of radiopharmaceuticals ad-ministered • High-resolution dynamic whole-body PET for the quantification of metabolic processes• Ultra-late PET imaging (with high latency after radiotracer injection) for a more accurate assessment of biological processes in humans and description of pharmacokinetics in vivoWe consider this new device as a milestone in molecular imaging, as the unique sensitivity and specificity opens up completely new research opportunities in various fields:• Development and testing of new (radio)pharmaceuticals; the requested PET/CT with enlarged FOV opens new opportunities for enhanced precision in diagnostics and therapy control in oncological diseases with very large synergies for our Cluster of excellence iFIT (image guided and Functionally Instructed Tumor therapies), with the aim of personalized control of complex oncological combination therapies.• Completely new research approaches in the field of immune imaging in cancer patients; individual prediction or early therapy stratification whether a personalized immune therapy is successful with significant economic savings potential for society • Multiparametric image analysis by artificial intelligence (cooperation with Max Planck Institute); AI-based evaluation of dynamic PET-imaging provides the most accurate representation of metabolic changes, e.g., in oncological, neurological, chronic inflammatory and cardiovascular diseases• Investigation of metabolic changes in non-oncological diseases with very low radiation exposure

正电子发射断层扫描（PET）通过使用放射性标记示踪剂（放射性药物）能够以高灵敏度和特异性检测体内代谢变化，可以特异性检测不同疾病的代谢变化或针对特定的目标结构（抗原或受体）。 PET被认为是无创评估体内空间和时间代谢变化的最准确的方法。与目前可用的设备（FOV 25 cm）相比，所需的 PET/CT 扫描仪具有 1 m 明显更大的轴向视野（FOV），因此灵敏度将提高 10 倍，并且空间和时间分辨率显着提高。因此，即使与 FOV 为 2 m 的类似原型相比，也可以实现以前未达到的用于检测分子变化的图像质量。因此，可以实施并进一步开发新的 PET/CT 检查程序，而这在现有技术中是不可能实现的： • 超快速全身 PET 检查（1-2 分钟，而不是 20 分钟），放射性药物的施用量不变 • 超低剂量 PET 检查，辐射暴露极低（0.5 mSv，而不是 6-12 mSv），因为更高的灵敏度可以大大减少 放射性药物的施用量 • 高分辨率动态全身 PET，用于量化代谢过程 • 超晚期 PET 成像（放射性示踪剂注射后具有高延迟），用于更准确地评估人体生物过程并描述体内药代动力学 我们认为这款新设备是分子成像领域的里程碑，因为其独特的灵敏度和特异性开辟了全新的领域 各个领域的研究机会：• 新（无线电）药物的开发和测试；所要求的具有扩大视场的 PET/CT 为提高肿瘤疾病的诊断和治疗控制精度提供了新的机会，与我们的卓越集群 iFIT（图像引导和功能指导肿瘤治疗）具有巨大的协同作用，旨在对复杂的肿瘤联合治疗进行个性化控制。• 癌症患者免疫成像领域的全新研究方法；个体预测或早期治疗分层个性化免疫治疗是否成功，并为社会带来巨大的经济节约潜力。 • 人工智能多参数图像分析（与马克斯·普朗克研究所合作）；基于人工智能的动态 PET 成像评估可最准确地表示代谢变化，例如肿瘤、神经、慢性炎症和心血管疾病• 在极低辐射暴露下研究非肿瘤疾病的代谢变化